GlassScriptPhysician profile
Heidi Bohlmann
NPI 1457388464
$2,040.91
in general payments reported to CMS, 2019-2025
26 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $198 · 2023: $500 · 2024: $911 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,843.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $323.74 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $239.59 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $150.88 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Glaxosmithkline, LLC. | $144.20 | 2023-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $141.18 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 | Jardiance |
| Penumbra, INC. | $113.59 | 2023 | Indigo System |
| Intuity Medical INC | $90.88 | 2022 | |
| Abbvie INC. | $87.13 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $84.91 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.71 | 2023-2024 | Xifaxan, Ibschek |
| Inari Medical, INC. | $82.08 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Pfizer INC. | $60.99 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $49.65 | 2023 | Spravato |
| Hologic Sales and Service, LLC | $47.95 | 2023-2024 | Thinprep 2000 Processor, Affirm Prone Biopsy System, Aptima |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $26.45 | 2024 | Flucelvax |
| Noven Therapeutics, LLC | $24.95 | 2025 | Xelstrym |
| Astellas Pharma US INC | $23.96 | 2025 | Veozah |
| Ibsa Pharma INC. | $22.05 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.25 | 2025 | |
| Exact Sciences Corporation | $19.89 | 2025 | Cologuard Collection Kit |
| Inogen, INC. | $17.42 | 2024 | |
| Shield Therapeutics INC | $15.95 | 2024 | |
| Currax Pharmaceuticals LLC | $15.10 | 2024 | Contrave |
| Merck Sharp & Dohme LLC | $14.39 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Lundbeck LLC | $14.02 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Bohlmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.